JP2021524247A5 - - Google Patents
Info
- Publication number
- JP2021524247A5 JP2021524247A5 JP2020565264A JP2020565264A JP2021524247A5 JP 2021524247 A5 JP2021524247 A5 JP 2021524247A5 JP 2020565264 A JP2020565264 A JP 2020565264A JP 2020565264 A JP2020565264 A JP 2020565264A JP 2021524247 A5 JP2021524247 A5 JP 2021524247A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antigen
- nucleic acid
- vector
- optionally
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675624P | 2018-05-23 | 2018-05-23 | |
| US62/675,624 | 2018-05-23 | ||
| PCT/US2019/033828 WO2019226939A1 (en) | 2018-05-23 | 2019-05-23 | Immune checkpoint inhibitor co-expression vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524247A JP2021524247A (ja) | 2021-09-13 |
| JP2021524247A5 true JP2021524247A5 (https=) | 2022-05-27 |
| JPWO2019226939A5 JPWO2019226939A5 (https=) | 2022-05-27 |
Family
ID=68617211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565264A Withdrawn JP2021524247A (ja) | 2018-05-23 | 2019-05-23 | 免疫チェックポイント阻害剤の共発現ベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210213122A1 (https=) |
| EP (1) | EP3796930A4 (https=) |
| JP (1) | JP2021524247A (https=) |
| KR (1) | KR20210013589A (https=) |
| CN (1) | CN112351793A (https=) |
| AU (1) | AU2019275070A1 (https=) |
| CA (1) | CA3099642A1 (https=) |
| TW (1) | TW202000906A (https=) |
| WO (1) | WO2019226939A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105190656B (zh) | 2013-01-17 | 2018-01-16 | 佩索纳里斯公司 | 用于遗传分析的方法和系统 |
| US10125399B2 (en) | 2014-10-30 | 2018-11-13 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
| US11299783B2 (en) | 2016-05-27 | 2022-04-12 | Personalis, Inc. | Methods and systems for genetic analysis |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| IL280890B2 (en) * | 2018-08-17 | 2025-10-01 | Gritstone Bio Inc | Antigen-binding protein that targets shared antigens |
| EP3877531A4 (en) * | 2018-11-07 | 2022-08-31 | Gritstone bio, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| EP4055610A4 (en) | 2019-11-05 | 2023-11-29 | Personalis, Inc. | ESTIMATION OF TUMOR PURITY FROM SINGLE SAMPLES |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| EP4168569A4 (en) * | 2020-06-18 | 2024-08-07 | Personalis, Inc. | Machine-learning techniques for predicting surface-presenting peptides |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| CA3216276A1 (en) | 2021-04-29 | 2022-11-03 | Yardena Samuels | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same |
| WO2023034881A1 (en) * | 2021-09-02 | 2023-03-09 | Elixirgen Therapeutics, Inc. | Temperature-controllable, rna immunotherapeutic for cancer |
| EP4413580A4 (en) | 2021-10-05 | 2025-08-13 | Personalis Inc | PERSONALIZED TESTS FOR PERSONALIZED CANCER MONITORING |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
| AU2002242016A1 (en) * | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| WO2004031210A2 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| US9402888B2 (en) * | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| MX2017002890A (es) * | 2014-09-03 | 2017-11-13 | Bavarian Nordic As | Métodos y composiciones para potenciar respuestas inmunitarias. |
| AU2016339924B2 (en) * | 2015-10-12 | 2020-01-02 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| AU2017225787B2 (en) * | 2016-03-03 | 2021-09-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2017226199A1 (en) * | 2016-03-04 | 2018-09-13 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| CA3022267A1 (en) * | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| PE20191345A1 (es) * | 2016-11-23 | 2019-09-30 | Gritstone Oncology Inc | Administracion viral de neoantigenos |
| WO2018161092A1 (en) * | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
-
2019
- 2019-05-23 EP EP19808512.8A patent/EP3796930A4/en active Pending
- 2019-05-23 KR KR1020207036367A patent/KR20210013589A/ko not_active Ceased
- 2019-05-23 TW TW108117922A patent/TW202000906A/zh unknown
- 2019-05-23 AU AU2019275070A patent/AU2019275070A1/en not_active Abandoned
- 2019-05-23 WO PCT/US2019/033828 patent/WO2019226939A1/en not_active Ceased
- 2019-05-23 US US17/058,113 patent/US20210213122A1/en not_active Abandoned
- 2019-05-23 CN CN201980044406.0A patent/CN112351793A/zh active Pending
- 2019-05-23 CA CA3099642A patent/CA3099642A1/en active Pending
- 2019-05-23 JP JP2020565264A patent/JP2021524247A/ja not_active Withdrawn
-
2024
- 2024-01-04 US US18/404,681 patent/US20250025544A1/en active Pending